Leadership
Our multidisciplinary team brings deep regulatory, scientific, clinical development, and business expertise to efficiently advance novel therapies from concept through regulatory approval. Through thoughtful clinical trial design and execution, we streamline development pathways to support the advancement of innovative immunotherapies.
Company Leadership
Gregory Glenn, MD
CEO
Dr. Greg Glenn is a seasoned biotech leader with a proven track record in vaccine development and executive management. Following a research fellowship at the Walter Reed Army Institute of Research, Dr. Glenn founded IOMAI Corporation, leading it from startup to IPO and acquisition. As President of R&D at Novavax Inc., he played a pivotal role in developing and licensing Nuvaxovid and securing key funding, including Operation Warp Speed. Dr. Glenn also contributed to the WHO-endorsed R21/Matrix Malaria Vaccine. He has published over 140 peer reviewed publications. In mid-2024, he became CEO of Pinion Immunotherapeutics, driving innovation in immunotherapy.
Renhuan Xu, PhD
CSO
Dr. Renhuan Xu is a distinguished expert in immunology with over 20 years of industry experience spanning cancer immunotherapy, infectious disease prevention, and vaccine development. He earned his Ph.D. in Immunology from Shanghai Jiaotong University, School of Medicine, and completed postdoctoral training at Fox Chase Cancer Center in Philadelphia, PA.
Dr. Xu is a co-founder of Pinion, where he has applied his extensive expertise to advance innovative solutions in immunotherapy and vaccine science.
Jianzhu Chen, PhD
Dr. Jianzhu Chen is a co-founder of Pinion and a renowned immunologist with over 30 years of experience in academia and biotechnology. He is a Professor of Immunology at the Massachusetts Institute of Technology (MIT) and a member of the prestigious Koch Institute for Integrative Cancer Research.
Dr. Chen earned his Ph.D. at Stanford University and completed postdoctoral training at Harvard University.
Katherine Langston
Director of Operations
BS/MS, University of North Carolina at Chapel Hill. Previously supported Phase III execution, BLA preparation, and commercialization planning at Kolon TissueGene. Leads operations and cross-functional strategic execution at Pinion, spanning clinical development, regulatory strategy, manufacturing, and corporate strategy.
Sia
CBO
Sia is currently leading BD at Pinion. She is a biotech entrepreneur and business development leader with over 20 years of experience across pharma, venture capital, alliance management, and BD, including over 10 years in a company working on RNA and DNA vaccines in the spaces that Pinion is focused on. She co-founded and operated a venture capital studio focused on accelerating early-stage biotech companies developing gene therapies and immunotherapies for complex medical illnesses. The studio and its affiliates raised more than $30M to seed its portfolio companies. Sia has built and executed go-to-market strategies for biotech including in the APAC region. Sia’s experience spans startup formation, fundraising, partnership development, and strategy, all of which she now brings to Pinion to help bridge science with business and investment opportunities.
Strategic Advisors
David Knipe, PhD
Higgins Professor of Microbiology and Molecular Genetics at Harvard Medical School
James Young, PhD
Scientist, Virologist, Innovator. Former President R&D, MedImmune.
Phil Krause, MD
Clinician Scientist, Virologist. Former Deputy Director, FDA.
Robert Redfield, MD
Public Health, Clinician-Scientist, Virologist. Former Director, CDC.
Richard Douglas
Scientist and corporate development leader. Former SVP Corporate Development, Genzyme. Board of Directors: Novavax (NVAX), Aldeyra (ALDX), MaxCyte (MXCT).
Stan Erck
Former President and Chief Executive Officer, Novavax, Inc.
Read full bio
Mr. Erck served as president and chief executive officer of Novavax, Inc., from 2011, and as a director of Novavax from 2009, until his retirement in January 2023.
Mr. Erck previously served as executive chairman of Novavax from 2010 to 2011 and interim chief financial officer from 2017 to 2018. From 2000 to 2008, Mr. Erck served as president and chief executive officer of Iomai Corporation, a developer of vaccines and immune system therapies, which was acquired in 2008 by Intercell AG.
He previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International. Within the past five years, Mr. Erck served on the board of directors of BioCryst Pharmaceuticals.
Mr. Erck received a BS in economics from the University of Illinois and an MBA from the University of Chicago. During his tenure as chief executive officer of Novavax, Mr. Erck led the company from preclinical development through global commercialization with first year revenues of $2 billion.